kabutan

Sumitomo Pharma Co., Ltd.(4506) Summary

4506
TSE Prime
Sumitomo Pharma Co., Ltd.
1,835.0
JPY
-31.0
(-1.66%)
Mar 13, 3:30 pm JST
11.51
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
1,817
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
7.1
PBR
2.52
Yield
ー%
Margin Trading Ratio
4.82
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
1,814.0 JPY 11.40 USD
Previous Close Mar 12
1,866.0 JPY 11.73 USD
High Mar 13, 10:19 am
1,887.0 JPY 11.86 USD
Low Mar 13, 9:03 am
1,813.0 JPY 11.39 USD
Volume
6,365,900
Trading Value
0.01T JPY 0.07B USD
VWAP
1851.83 JPY 11.62 USD
Minimum Trading Value
183,500 JPY 1,151 USD
Market Cap
0.73T JPY 4.59B USD
Number of Trades
14,235
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
15,939
1-Year High Feb 20, 2026
143,709
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 256,500 11,470,700 44.72
Feb 27, 2026 297,100 10,487,400 35.30
Feb 20, 2026 326,200 10,761,100 32.99
Feb 13, 2026 261,400 8,556,400 32.73
Feb 6, 2026 210,000 9,306,100 44.31
Company Profile
Sumitomo Pharma Co., Ltd. is a mid-sized pharmaceutical company originating from the Sumitomo Chemical group. The company focuses on developing drugs in the areas of psychiatry and neurology, oncology, and regenerative medicine.
Sector
Pharmaceuticals
Sumitomo Pharma's core business is the manufacturing, procurement, and sales of prescription pharmaceuticals, while also dealing with medical devices. The company prioritizes psychiatry, neurology, and oncology as its key therapeutic areas. In Japan, Sumitomo Pharma conducts manufacturing and sales of prescription pharmaceuticals through its subsidiaries. Additionally, through a joint venture with its parent company Sumitomo Chemical, it engages in contract development and manufacturing in the field of regenerative medicine and cell therapy. Sumitomo Pharma is also actively expanding globally, with operations in North America, China, Southeast Asia, and Taiwan. The company has established subsidiaries in various regions to conduct local pharmaceutical manufacturing, sales, and information provision activities.